comparemela.com
Home
Live Updates
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society : comparemela.com
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
Long-term treatment with KarXT was associated with continued improvements in symptoms of schizophrenia across all efficacy measures at 52 weeks
More than 75% of participants achieved
Related Keywords
Italy
,
Roland Chen
,
Bristol Myers Squibb
,
Instagram
,
Cenexel Hassman Research Institute
,
Exchange Commission
,
Twitter
,
Facebook
,
Youtube
,
Schizophrenia International Research Society
,
Linkedin
,
Annual Congress
,
Bristol Myers
,
Negative Syndrome Scale
,
Clinical Global Impression Severity
,
Elan Cohen
,
Oral Session
,
New Pharmacological Treatments
,
Myers Squibb
,
Delivering Breakthrough Science
,
Meaningful Interventions
,
Private Securities Litigation Reform Act
,
Annual Report
,
Quarterly Reports
,
Current Reports
,
comparemela.com © 2020. All Rights Reserved.